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agents cause limited damage. How-
ever, more malignant forms of “auto-
mutilating” hoaxes are likely to
emerge that could be as devastating to
computers as some autoimmune dis-
eases are to humans.
The electronic monoculture that
improves communication also
increases the risk for contagion. Pre-
dominant use of a single operating
system has improved communication
and sharing of electronic data but has
also facilitated ready amplification of
virulent programs. As with biological
infection, transmission of computer
infection depends on susceptibility of
the population. Virus producers saw
an opportunity in the popular prefer-
ence worldwide for PCs with
Microsoft Windows operating sys-
tems. The enormous popularity of
these systems, along with their long-
recognized inadequate protection
against misuse, made computer users
susceptible. Virtual viruses able to
infect multiple operating systems are
rare (as are biological viruses with
broad host specificity), and even when
infected, computers that run on differ-
ent operating systems (e.g., Mac,
Unix) or other-than-Outlook e-mail
programs usually are dead-end hosts
for PC viruses.
Pathogens do not reinvent the
wheel. Virulence genes are constantly
“stolen” and reused. Thus, new com-
binations of virulence genes can result
in new pathogenic strategies, and such
combinations frequently accumulate
in pathogenicity islands. Reuse and
combination of effective (and infec-
tive) strategies are also common in
computer malware. A recent example
demonstrates the value of just the right
amount of virulence. A highly danger-
ous worm called Nimda (Admin in
reverse) was released exactly 1 week
after the September 11, 2001, terrorist
attack in the United States. Nimda
combined the most powerful strategies
of Code Red and SirCam and spread
more rapidly than any previous worm.
Clicking on the subject line of an
infected e-mail (to delete it, for
instance) itself activated the worm.
However, because of the immensity of
the threat, the Internet community
responded extremely rapidly. Within
hours after its release, alerts to system
administrators on how to block the
worm had effectively slowed its
spread. Early surveillance and barrier
development averted disaster. As in
contained epidemics of hemorrhagic
fevers, the immense threat of high
contagion and lethality prompts effec-
tive measures to rapidly recognize
outbreaks and prevent pandemics. 
The types of measures to be used
against computer contagion can be
learned from biology. Immune effec-
tors of plants and animals protect
against a broad range of pathogens;
however, in nature this system
evolved over millions of years. Engi-
neering protective computer systems
with similar efficacy within a few
years is a great challenge. Current pro-
tection programs mainly resemble
innate immunity, but programs that
learn from exposure (thus resembling
adaptive immunity) are under devel-
opment. Vaccination with relatively
harmless microbes primes the immune
system. Biological hosts also naturally
carry protective microflora that com-
pete with pathogens. Could we pro-
duce “virtual vaccines” that are
beneficial to the computers carrying
them (e.g., by blocking preferred sites
of entrance for viruses or repairing
viral damage automatically) and let
these “good” microbes circulate on the
Internet just as malignant viruses do?
Crude versions of such vaccines have
already been developed. Recently, a
worm by the name Fixing the Holes
was discovered that utilized known
security holes to spread to other hosts.
Using “good” microbes would have its
costs: occupation of Internet capacity
and consequent slowdown of data
transmission and presence of mali-
cious worms disguised as beneficial
ones to elude detection. 
Knowledge of infectious diseases
may help control computer contagion.
Conversely, study of computer mal-
ware may help curb infectious disease
emergence. Internet contagion illus-
trates how pathogens emerge and
spread in our increasingly small
world. The speed of virtual pathogen
evolution makes it possible to follow
the process of mutation and selection
in real-time. With countless inter-
linked computers, the risk for virtual
contagion is so great that urgent steps
are needed to avoid catastrophe. How
many pandemics will it take before we
accept the risks and costs of computer
immunity? Similarly, to protect
against emerging pathogens, we must
use all tools available, including vir-
tual pandemics. A task force to collect
data on the epidemiology of virtual
infections as a model for infectious dis-
eases might be an important first step.
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To the Editor: The Indian Ocean
was free of cholera for decades, until
January 1998, when an outbreak was
detected in Comoros Islands (1). On
March 23, 1999, the Malagasy Epide-
miological Surveillance System
reported the first case of cholera in
Mahajanga, a harbor on the northwest
coast (2). In May 1999, the Malagasy
sanitary authorities set up sanitary bar-
ricades at the borders of the two prov-
inces—Mahajanga and Antananarivo
—affected by the epidemic. Oral dox-
ycycline was systematically given toEmerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 337
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all the travelers crossing the barri-
cades. In addition, doctors in hospitals
and dispensaries in these two prov-
inces gave doxycycline to patients
with acute diarrhea. Despite these
measures, cholera had reached all six
provinces of the island 10 months
later. In June 1999, a specific cholera
surveillance system was established in
every Malagasy province with close
collaboration between the Malagasy
Ministry of Health and the Institut
Pasteur de Madagascar.
The first strain isolated in
Mahajanga was Vibrio cholerae sero-
group O1, serotype Ogawa, biotype El
Tor. Its antibiotype showed resistance
to trimethoprim-sulfamethoxazole,
sulfonamides, trimethoprim, chloram-
phenicol, streptomycin, and vibrio-
static agent O129 (a molecule
naturally active against V. cholerae
and used for identification). Suscepti-
bility was conserved for tetracycline,
ampicillin, cephalotin, and pefloxacin
(2). This strain showed a rRNA gene
restriction pattern similar to those of
African and Comorian strains isolated
since 1994 and 1998, respectively (2,3).
From July 1999 to March 2001,
we monitored the tetracycline resis-
tance of V. cholerae isolated from the
stool samples sent to the Institut Pas-
teur de Madagascar in Antananarivo,
using the standard disk-diffusion
method (4). Stool samples were col-
lected in sterile containers, on What-
man paper, or on rectal swabs.
Isolation of V. cholerae was carried
out immediately after reception. Every
V. cholerae strain identified belonged
to serogroup O1, biotype El Tor. All the
tetracycline-resistant  V. cholerae iso-
lated and 60 randomly selected tetracy-
cline-susceptible strains were tested for
sensitivity to the following drugs:
ampicillin, cephalotin, doxycycline,
sulfonamide, trimethoprim, trimethop-
rim-sulfamethoxazole, chlorampheni-
col, streptomycin, spectinomycin,
neomycin, kanamycin, nalidixic acid,
pefloxacin, erythromycin, rifampicin,
and nitrofurantoin, as well as to vibrio-
static agent 0129.
During the study period, we iso-
lated 351 (46.1%) V. cholerae strains
from 761 stool samples analyzed. The
provinces of Antananarivo, Mahajanga,
and Toliary accounted for 85.9% of the
stool samples sent to our laboratory.
From these provinces, we isolated 288
strains; by contrast, from the three
other provinces (Antsiranana, Fian-
arantsoa, and Toamasina, located on
the east coast), 63 strains were iso-
lated. Rates of isolation, tested by a
chi-square test, did not differ signifi-
cantly between the six provinces
(p=0.32).
Fifty five (15.7%) of the 351
strains isolated were found to be tetra-
cycline resistant (cross-resistance with
doxycycline) but had the same resis-
tance pattern as the index strain iso-
lated in Mahajanga for the other
antibiotics tested. During the first
rainy season following the epidemic
(November 1999 to March 2000), a
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unique tetracycline-resistant strain
was isolated (in February 2000), in the
capital Antananarivo; it was also resis-
tant to ampicillin, nalidixic acid, and
nitrofurantoin. During the dry season
(from April to October 2000), five
(13.2%) of 38 V. cholerae new tetracy-
cline-resistant strains were found.
However, during the last rainy season
(November 2000 to March 2001), 49
(69 %) of 71 strains isolated were tet-
racycline resistant. They were mainly
from the city and suburbs of Antanan-
arivo (95.3%, 41/43 strains). The eight
other resistant strains came from the
provinces of Antananarivo, Toliary,
and Fianarantsoa. 
As observed in Tanzania (5), the
extensive prophylactic use of tetracy-
cline may have triggered the rapid
emergence and spread of tetracycline-
resistant strains in Madagascar. The
high rate of resistance in Antanan-
arivo, where the major Malagasy hos-
pitals are located, could be due to
easier access to drugs in the capital
than in the other provinces.
Of the 60 randomly selected tetra-
cycline-susceptible strains, 56 had the
original antibiotype; four became sus-
ceptible to vibriostatic agent O129 and
to all the antibiotics tested, except tri-
methoprim. Four (3.5%) of the 115
strains tested (55 tetracycline-resis-
tant and 60 tetracycline-susceptible
strains) on a large panel of antibiotics
were susceptible to trimethoprim-sul-
famethoxazole. As usually observed in
other African cholera-endemic coun-
tries (6), only a small proportion of the
strains were susceptible to trimetho-
prim-sulfamethoxazole, one of the
most frequently dispensed drugs.
Faced with this first emergence of
cholera in Madagascar and its rapid
spread, medical authorities reacted
immediately by using doxycycline as
chemoprophylaxis (contrary to World
Health Organization recommendations
[7]), probably because of its easy
availability.
Our study demonstrates that 2
years after the epidemic began, neither
trimethoprim-sulfamethoxazole nor
tetracycline, the two first-line drugs
used in Madagascar, can be recom-
mended any longer for treating severe
cases of cholera. This may represent a
critical public health problem in the
country, especially as most of the pop-
ulation cannot afford more effective
but expensive antibiotics.
Therefore, Malagasy medical
authorities should a) abandon any sys-
tematic chemoprophylaxis, b) advise
only oral rehydration therapy for mild-
to-moderate cases, and c) reserve anti-
biotic therapy for severe illness (7).
These measures against the cholera
epidemic should be accompanied by
general reinforcement of microbio-
logic surveillance to monitor antibi-
otic resistance so that the island can
respond effectively to any future bac-
terial epidemics.
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